Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.

25.07 0.68 −2.64%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
16.2×
Dividend yield
—
F-score
7/9
Altman Z
11.56
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 4 6 5

+8 more TTM periods

ROE
(72.31%) (42.02%) (26.72%) (18.46%)
ROA
(37.25%) (22.72%) (20.04%) (14.34%)
ROIC
0.00% 0.00% (144.67%) (64.78%)
Return on Tangible Assets
(56.58%) (28.13%) (36.55%) (23.89%)
Average Days of Receivables
58.30 20.99 15.98 79.67
Free Cash Flow per Share
(1.65) (1.03) (0.47) (0.87)
Free Cash Flow
(120.54) (77.04) (35.36) (66.20)
Other line items

Show all line items

Columns are period end dates